WO2003066680A2 - Antigens for immunocontraception - Google Patents
Antigens for immunocontraception Download PDFInfo
- Publication number
- WO2003066680A2 WO2003066680A2 PCT/CA2003/000177 CA0300177W WO03066680A2 WO 2003066680 A2 WO2003066680 A2 WO 2003066680A2 CA 0300177 W CA0300177 W CA 0300177W WO 03066680 A2 WO03066680 A2 WO 03066680A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mammal
- seq
- zona pellucida
- polypeptide
- czp
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title description 46
- 102000036639 antigens Human genes 0.000 title description 46
- 108091007433 antigens Proteins 0.000 title description 46
- 210000004340 zona pellucida Anatomy 0.000 claims abstract description 53
- 229960005486 vaccine Drugs 0.000 claims abstract description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 45
- 229920001184 polypeptide Polymers 0.000 claims abstract description 43
- 241000124008 Mammalia Species 0.000 claims abstract description 28
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 7
- 230000036512 infertility Effects 0.000 claims description 6
- 208000000509 infertility Diseases 0.000 claims description 6
- 231100000535 infertility Toxicity 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 241000282326 Felis catus Species 0.000 abstract description 51
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 29
- 230000002796 immunocontraceptive effect Effects 0.000 abstract description 16
- 241000282341 Mustela putorius furo Species 0.000 abstract description 13
- 241000772415 Neovison vison Species 0.000 abstract description 8
- 230000035558 fertility Effects 0.000 abstract description 8
- 239000002502 liposome Substances 0.000 description 31
- 239000002671 adjuvant Substances 0.000 description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940037003 alum Drugs 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 230000009260 cross reactivity Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 241000283014 Dama Species 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 108700012941 GNRH1 Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108010074006 Zona Pellucida Glycoproteins Proteins 0.000 description 3
- 102000008937 Zona Pellucida Glycoproteins Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 229940049964 oleate Drugs 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000767092 Ciliata mustela Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000283118 Halichoerus grypus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241001530054 Cystophora cristata Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241001529469 Phoca groenlandica Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101100545388 Sus scrofa ZP4 gene Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000145 adjuvantlike effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229940124462 contraceptive vaccine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to the field of immunology, in particular, to immunocontraceptive vaccines.
- IC immunocontraception
- IC can be a humane means of reducing fertility in domestic, feral and wild mammals (Oogjes, 1997), and several potential IC targets exist.
- GnRH gonadotrophin-releasing hormone
- a vaccine that used gonadotrophin-releasing hormone (GnRH) as antigen depressed ovarian activity in horses for one breeding season (Bradley et al . , 1999).
- GnRH gonadotrophin-releasing hormone
- the difficulty with GnRH directed vaccines is that there is a potential for endocrine dysfunction (Muller et al . , 1997) .
- ZP Zona pellucida
- This structure is an ideal candidate for a contraceptive target, since altering its structure can prevent pregnancy.
- ZP immunisation has been effective in lowering fertilisation rates of many mammals (Willis et al . , 1994; Kirkpatrick et al . , 1996; 1996; Brown et al . , 1997a, b; Harris et al . , 2000) .
- pig zona pellucida is an effective immunocontraceptive (although requires multiple boosters) in domestic cats (Ivanova et al . , 1995; Bradley et al . , 1999) .
- Porcine zona pellucida has also been used in liposome-based immunocontraceptive vaccines for reducing fertility of certain mammals by 90-100% with a multi-year efficacy (Brown et al . , 2001).
- use of pZP in such a liposome-based vaccine as a single administration vaccine for cats is ineffective in cats.
- an immunocontraceptive vaccine for cats and/or dogs comprising a zona pellucida polypeptide, and/or a variant thereof, from a carnivorous mammal and a physiologically acceptable auxiliary.
- a method for reducing fertility in cats and/or dogs comprising administering to a cat or a dog an immunocontraceptive vaccine comprising a zona pellucida polypeptide, and/or a variant thereof, from a carnivorous mammal and a physiologically acceptable auxiliary.
- a zona pellucida polypeptide and/or a variant thereof, from a carnivorous mammal for reducing fertility in cats and/or dogs or for preparing a medicament for reducing fertility in cats and/or dogs.
- composition comprising the polypeptide described above and a carrier or diluent suitable for use in a vaccine.
- kits for inducing L5 infertility in a mammal comprising the polypeptide described above and instructions for its use in eliciting an immune response against native zona pellucida in a mammal.
- a method for inducing anti-ZPB antibodies in a mammal comprising 20 administering to the mammal at least one polypeptide described above, wherein said administering induces production of an antibody that binds mammalian zona pellucida.
- Figure 1 is a graph showing the production of anti-SIZP antibodies by rabbits immunised with porcine zona pellucida (pZP) or cat zona pellucida (cZP) encapsulated in liposomes with either FCA or alum adjuvant as a single administration delivery system.
- pZP porcine zona pellucida
- cZP cat zona pellucida
- Figure 2 is a Western blot of a gel electrophoresis of dZP (lanes A and B) , feZP (lanes C and D) , cZP (lane E) and pZP (lanes F and G) probed with rabbit anti-cZP antibodies showing the cross-reactivity of rabbit anti-cZP antibodies to cZP, dZP, pZP, and feZP.
- Figure 3 is a Western blot of a gel electrophoresis of mZP (lanes A, B, and C) probed with rabbit anti-pZP antibodies (lane A) and rabbit anti-cZP antibodies (lanes B and C) showing the cross-reactivity of rabbit anti-cZP and anti-pZP antibodies to mZP.
- Figure 4 shows an alignment of a number of mammalian zona pellucida sequences.
- Figure 5 shows alignments of specific zona pellucida sequences between various species.
- Figure 6 is a schematic depiction of the alignment of the zona pellucida sequences.
- ZP Zona pellucida
- IC immunocontraception
- ZP antigens from carnivorous mammals are particularly useful in preparing immunocontraceptive vaccine that are capable of producing immune responses in cats and/or dogs.
- ZPB is particularly useful as the antigen.
- the carnivorous mammals may be selected from the group consisting of cat (e.g. Fells catus) , dog (e.g. Canis familiaris) , ferret (e.g. Mustela putorius furo) , and mink (e.g. Mustela viso ⁇ ) .
- cat ZP (cZP) , dog ZP (dZP) , ferret ZP (feZP) , mink ZP (mZP) and/or variants thereof are particularly useful as antigens in the immunocontraceptive vaccine.
- cat ZPB cZPB
- dog ZPB dZPB
- ferret ZPB feZPB
- mink ZPB mZPB
- variants are preferred.
- ⁇ ariants' means recombinant or denatured proteins or peptides, or fragments thereof, or fragments of native ZP, which are capable of producing the desired immune response in cats and/or dogs. Substitutions, additions and/or deletions of native or recombinant ZP are encompassed by variants. Variants are generally at least 50% homologous to native ZP.
- Variants having homology of at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% to the native ZP are also particularly contemplated within the scope of the invention.
- Fragments of native, recombinant or denatured ZP proteins or peptides are generally at least 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 44, 46, 48 or 50 amino acids in length.
- such fragments include amino acids
- VSTTQSPGTSRPPTPASRVTPQ amino acid numbers 29 to 50 of cat zona pellucida
- PRNPPDQALVSSLSPS amino acid numbers 79 to 94 of cat zona pellucida
- VRTTQSPQMLRTPAPPSGVTPQ (from SEQ ID NO 6)
- PTLLSSLSYSPDQNR (from SEQ ID NO 8) .
- polypeptides of the invention include any combination of the above fragments and their consensus sequences.
- isolated polynucleotide is defined as a polynucleotide removed from the environment in which it naturally occurs.
- a naturally-occurring DNA molecule present in the genome of a living bacteria or as part of a gene bank is not isolated, but the same molecule separated from the remaining part of the bacterial genome, as a result of, e . g. , a cloning event (amplification), is isolated.
- an isolated DNA molecule is free from DNA regions ( e . g. , coding regions) with which it is immediately contiguous at the 5' or 3 ' end, in the naturally occurring genome.
- Such isolated polynucleotides may be part of a vector or a composition and still be defined as isolated in that such a vector or composition is not part of the natural environment of such polynucleotide.
- the present invention includes amino acid sequences which are homologous to SEQ ID NOS : 2 , 4 , 6 and 8 , and the fragments above.
- homologous amino acid sequence is any polypeptide which is encoded, in whole or in part, by a nucleic acid sequence which hybridizes at 25-35°C below critical melting temperature (Tm) , to any portion of the nucleic acid sequence of SEQ ID NOS: 1, 3, 5 or 7.
- Tm critical melting temperature
- a homologous amino acid sequence may be one that differs from an amino acid sequence shown in SEQ ID NOS: 2, 4, 6 or 8 by one or more conservative amino acid substitutions .
- homologous amino acid sequences include sequences that are identical or substantially identical to SEQ ID NOS: 2, 4, 6 or 8.
- amino acid sequence substantially identical is meant a sequence that is at least 90%, preferably 95%, more preferably 97%, and most preferably 99% identical to an amino acid sequence of reference and that preferably differs from the sequence of reference by a majority of conservative amino acid substitutions.
- amino acids having uncharged polar side chains such as asparagine, glutamine, serine, threonine, and tyrosine
- amino acids having basic side chains such as lysine, arginine, and histidine
- amino acids having acidic side chains such as aspartic acid and gluta ic acid
- amino acids having nonpolar side chains such as glycine, alanine, valine, leucine, ' isoleucine, proline, phenylalanine, methionine, tryptophan, and cysteine .
- sequence analysis software such as Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705. Amino acid sequences are aligned to maximize identity. Gaps may be artificially introduced into the sequence to attain proper alignment. Once the optimal alignment has been set up, the degree of homology is established by recording all of the positions in which the amino acids of both sequences are identical, relative to the total number of positions.
- homologous polynucleotide sequences are defined in a similar way.
- a homologous sequence is one that is at least 45%, more preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, and even more preferably 85%, 87%, 90%, 93%, 96% and most preferably 99% identical to SEQ ID NOS: 1, 3, 5 or 7.
- a fusion polypeptide is one that contains a polypeptide or a polypeptide derivative of the invention fused at the N- or C-terminal end to any other polypeptide.
- a simple way to obtain such a fusion polypeptide is by translation of an in-frame fusion of the polynucleotide sequences, i.e., a hybrid gene.
- the hybrid gene encoding the fusion polypeptide is inserted into an expression vector which is used to transform or transfect a host cell.
- the polynucleotide sequence encoding the polypeptide or polypeptide derivative is inserted into an expression vector in which the polynucleotide encoding the peptide tail is •• already present.
- a second aspect of the invention encompasses (i) an expression cassette containing a DNA molecule of the invention placed under the control of the elements required for expression, in particular under the control of an appropriate promoter; (ii) an expression vector containing an expression cassette of the invention; (iii) a procaryotic or eucaryotic cell transformed or transfected with an expression cassette and/or vector of the invention, as well as (iv) a.process for producing a .
- polypeptide or polypeptide derivative encoded by a polynucleotide of the invention which involves culturing a procaryotic or eucaryotic cell transformed or transfected with an expression cassette and/or vector of the invention, under conditions that allow expression of the DNA molecule of the invention and, recovering the encoded polypeptide or polypeptide derivative from the cell culture.
- a recombinant expression system is selected from procaryotic and eucaryotic hosts.
- Eucaryotic hosts include yeast cells (e . g. , Sac cha omyces cerevisiae or Pichia pastoris) , mammalian cells ( e . g. , COS1, NIH3T3, or JEG3 cells), arthropods cells (e.g., Spodoptera frugiperda (SF9) cells), and plant cells.
- a preferred expression system is a procaryotic host such as E. coli .
- Bacterial and eucaryotic cells are available from a number of different sources including commercial sources to those skilled in the art, e. g. , the American Type Culture Collection (ATCC; Rockville, Maryland) . Commercial sources of cells used for recombinant protein expression also provide -instructions for usage of the cells.
- Antigens of the present invention may be formulated into vaccines in a number of ways. Methods of 5 formulating vaccines in general are well known to those skilled in the art (for example, see Harlow et al . , 1988 the disclosure of which is herein incorporated by reference) . Ivanova et al . , 1995; Bradley et al . , 1999; and Brown et al . , 2001, the disclosures of which are herein incorporated
- Immunocontraceptive vaccines comprising the ZP antigens of the present invention may be formulated as either single or multiple administration vaccines. Single administration vaccines using a system
- L5 such as that described in Brown et al . , 2001 are preferred.
- the amount of ZP antigen used in a dose of the immunocontraceptive vaccine can vary depending on the source of the antigen and the size of the cat or dog. One skilled in the art will be able to determine, without undue
- the effective amount of antigen to use in a particular application falls in the range from about 15 ⁇ g to about 2 mg per dose.
- the range is from about 20 ⁇ g to about 2 mg per dose, more preferably from about 20 ⁇ g to about 200 ⁇ g, and
- the amount ⁇ for a small animal is about 50 ⁇ g per dose while for a large animal it is about 100 ⁇ g per dose.
- auxiliaries for immunocontraceptive vaccines are generally known in the art.
- SO Auxiliaries include carriers, diluents, adjuvants and any other typical vaccine ingredients.
- Carriers and/or diluents are generally well known in the art.
- aqueous solutions, aqueous emulsions of an oil such as mineral oil, and non-aqueous media such as pure mineral oil may be used as carriers and/or diluents.
- Suitable adjuvants include alum, other compounds of aluminum, Bacillus of Calmette and Guerin (BCG) , TiterMaxTM, RibiTM, Freund' s Complete Adjuvant (FCA) and a new adjuvant disclosed by the United States Department of Agriculture's (USDA) National Wildlife Research Center on their web site at http: //www. aphis .usda .gov/ws/nwrc/pzp .htm based on Johne's antigen. Alum, .other compounds of aluminum, TiterMaxTM and the new USDA adjuvant are preferred.
- Alum is particularly preferred as the adjuvant.
- Alum is generally considered to be any salt of aluminum, in particular, the salts of inorganic acids. Hydroxide and phosphate salts are particularly useful as adjuvants.
- a suitable alum adjuvant is sold under the trade name, ImjectAlumTM (Pierce Chemical Company) that consists of an aqueous solution of aluminum hydroxide (45 mg/ml) and magnesium hydroxide (40 mg/ml) plus inactive stabilizers.
- ImjectAlumTM Pierce Chemical Company
- Alum is a particularly advantageous adjuvant since it already has regulatory approval and it is widely accepted in the art .
- the amount of adjuvant used depends on the amount of antigen and on the type of adjuvant. One skilled in the art can readily determine the amount of adjuvant needed in a particular application.
- a suitable quantity of ImjectAlumTM may range from 0.1 ml/dose of vaccine to 0.5 ml/dose.
- Liposomes are another typical vaccine ingredient.-
- Liposomes are completely closed lipid bilayer membranes containing an entrapped aqueous volume. Liposomes may be unilamellar vesicles (possessing a single bilayer membrane) or multilamellar vesicles (onion-like structures characterized by multimembrane bilayers, each separated from the next by an aqueous layer. Although any liposomes may be used, including liposomes made from archaebacterial lipids, particularly useful liposomes use phospholipids and unesterified cholesterol in the liposome formulation. The cholesterol is used.
- Phospholipids that are preferably used in the preparation of liposomes are those with at least one head group selected from the group consisting of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine and phosphoinositol .
- the amount of lipid used to form liposomes depends on the antigen being used but is typically in a range from about 0.05 gram to about 0.5 gram per dose of vaccine. Preferably, the amount is about 0.1 gram per dose. When unesterified cholesterol is also used in liposome formulation, the cholesterol is used in an amount equivalent to about 10% of the amount of lipid. The preferred amount of cholesterol is about 0.01 gram per dose of vaccine. If a compound other than cholesterol is used to stabilize the liposomes, one skilled in the art can readily determine the amount needed in the formulation.
- the vaccine composition may be formulated by: encapsulating the antigen or an antigen/adjuvant complex in liposomes to form liposome- encapsulated antigen and mixing the liposdme-encapsulated ' antigen with a carrier. If an antigen/adjuvant complex is not used in the first step, a suitable adjuvant may be added to the liposome-encapsulated antigen, to the mixture of liposome-encapsulated antigen and carrier, or to the carrier before the carrier is mixed with the liposome-encapsulated antigen. The order of the process may depend on the type of adjuvant used.
- the adjuvant and the antigen are mixed first to form an antigen/adjuvant complex followed by encapsulation of the antigen/adjuvant complex with liposomes.
- the resulting liposome-encapsulated antigen is then mixed with the carrier.
- liposome- encapsulated . antigen may refer to encapsulation of the antigen alone or to the encapsulation of the antigen/adjuvant complex depending on the context.
- the antigen may be first encapsulated in liposomes and the resulting liposome-encapsulated antigen is then mixed into the adjuvant in a carrier.
- Liposome-encapsulated antigen may be freeze-dried before being mixed with the carrier.
- an antigen/adjuvant complex may be encapsulated by liposomes followed by freeze-drying.
- the antigen may be encapsulated by liposomes followed by the addition of adjuvant then freeze-drying to form a freeze-dried liposome- encapsulated antigen with external adjuvant.
- the antigen may be encapsulated by liposomes followed by freeze-drying before the addition of adjuvant.
- Formulation of the liposome-encapsulated antigen into a hydrophobic substance may also involve the use of an emulsifier to promote more even distribution of the liposomes in the carrier.
- Typical emulsifiers are well known in the art and include mannide oleate (ArlacelTM A) , lecithin, TweenTM 80, SpansTM 20, 80, 83 and 85. Mannide oleate is a preferred emulsifier.
- the emulsifier is used in an amount effective to promote even distribution of the liposomes.
- the volume ratio (v/v) of carrier to emulsifier is in the range of about 5:1 to about 15:1 with a ratio of about 10:1 being preferred.
- Vaccine compositions may be administered parenterally (including intramuscularly, sub-cutaneously) or rectally. Parenteral administration is preferred.
- unit dosage forms are ampoules .
- Techniques that deliver the vaccine by injection and by remote delivery using darts, spring loaded syringes with jab sticks, air/carbon dioxide powered rifles, Wester gun and/or BallistivetTM biobullets and retain the biological activity are particularly preferred.
- the SIZP was encapsulated in liposomes formed using soybean L- ⁇ -lecithin (Calbiochem-Novabiochem, San Diego, CA, USA) and cholesterol (Calbiochem-Novabiochem) in a ratio of 10:1.
- Single administration vaccines were formulated with 1 of 2 adjuvants, i.e. with Freund' s complete adjuvant (FCA) or with alum.
- FCA Freund' s complete adjuvant
- a single dose of the vaccine with alum contained pZP (100 ⁇ g) and alum (Imject®alum, Pierce Chemical Co., Rockford, IL, USA) encapsulated in multilamellar liposomes (0.1 g lecithin and 0.01 g cholesterol) that were suspended in saline (0.15 mL) and emulsified in mineral oil/mannide oleate (8.5:1.5, v:v, 0.25mL) .
- Rabbits were immunised with pZP in either vaccine with FCA or vaccine with alum or with cZP in vaccine with FCA.
- Serum samples were taken monthly to measure the production of anti-SIZP antibodies. Production of anti-SIZP antibodies was measured as described by Brown et al . (1997b) , the disclosure of which is herein incorporated by reference, using protein A/alkaline phosphatase.
- the blots were washed 5X with TBS-TweenTM and then incubated with peroxidase labelled secondary antibody (goat anti- ' rabbit Ig, Jackson, 1:8000 in TBS-TweenTM) for 30 minutes at room temperature. Blots were then washed 5X with TBS-TweenTM and signals were detected by chemiluminescence (Santa Cruz) using X-ray film.
- peroxidase labelled secondary antibody goat anti- ' rabbit Ig, Jackson, 1:8000 in TBS-TweenTM
- Another row in each plate received doubling dilutions of a reference rabbit anti-pZP serum. Titers were determined using the linear portion of the titration curve and all titers are expressed as a percentage of the reference serum to control for interassay variability .
- Rabbits immunised with pZP or cZP produced similar anti-SIZP titers 2 months post-immunisation although the anti-cZP titer was lower than the anti-pZP titers obtained with either vaccine with FCA or vaccine with alum 1 month post-immunisation (Figure 1) . This may be due to less antigen being placed in the vaccine (1/2 the content of pZP) .
- One skilled in the art can predict that production of anti-cZP antibodies will continue to increase and yield a titer similar to the anti-pZP titers. Such titers have been shown to be immunocontraceptive in a variety of mammals.
- Cross-reactivity can also be measured by ELISA.
- titers of two cat anti-pZP sera were measured using pZP, the titers were 41% and 15% of the reference serum.
- titers of the same antisera were measured using cZP, the titers were 2% and 2% of the reference serum. This indicates that antibodies raised in cats against pZP have little affinity for cZP and consequently cat oocytes.
- the titers of two rabbit anti-cZP sera were measured using pZP, the titers were 7% and 40% of the reference serum.
- titers of the same antisera were measured using cZP, the titers were 32% and 200% of the reference serum.
- SEQ ID NO. 1 is the partial ferret DNA sequence that codes for the equivalent- of cat ZPB amino acid region 309-428. (Cat ZPB, including the leader sequence, is a total of 570 amino acids in length. )
- This ferret sequence was cloned by reverse transcription/degenerate PCR method. Primers were based on multiple alignments that included ZPB sequences from cat, cow, human, possum, mouse, rat and pig ZPB. A search of GenBankTM indicates that SEQ ID NO. 1 matches best with cZPB, suggesting that feZP will have many epitopes in common with ' cZP and therefore will be effective as an antigen in a cat immunocontraceptive vaccine.
- ferret partial amino acid sequence corresponding to the nucleotide sequence above is given by SEQ ID No. 2:
- SEQ ID NO. 3 is the partial nucleotide sequence of Canine ZPB . ( SEQ ID NO . 3 ) :
- the dog partial amino acid sequence corresponding to the nucleotide sequence above is given by SEQ ID NO. 4. -.
- SEQ ID NO. 5 is another partial ferret DNA sequence that codes for SEQ ID NO 6.
- SEQ ID NO. 7 is another partial dog DNA sequence that codes for SEQ ID NO 8.
- GSVTRDS IFRLRVSCSYSISSNAFPVNVHVFTFPPPHSETQPGPLTLELKIAKDKHYGSY YTAGDYP WKLLRDP I YVEVS I RHRTDPHLGLLLHYCWATP SR1TPQHQPQWLMLVKGC P
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003244428A AU2003244428A1 (en) | 2002-02-08 | 2003-02-10 | Antigens for immunocontraception |
EP03737229A EP1474447A2 (en) | 2002-02-08 | 2003-02-10 | Antigens for immunocontraception |
US10/636,620 US7056515B2 (en) | 2002-02-08 | 2003-08-08 | Antigens for immunocontraception |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35452502P | 2002-02-08 | 2002-02-08 | |
US60/354,525 | 2002-02-08 | ||
US38029302P | 2002-05-15 | 2002-05-15 | |
US60/380,293 | 2002-05-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/636,620 Continuation-In-Part US7056515B2 (en) | 2002-02-08 | 2003-08-08 | Antigens for immunocontraception |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003066680A2 true WO2003066680A2 (en) | 2003-08-14 |
WO2003066680A3 WO2003066680A3 (en) | 2003-11-13 |
Family
ID=27737462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2003/000177 WO2003066680A2 (en) | 2002-02-08 | 2003-02-10 | Antigens for immunocontraception |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1474447A2 (en) |
AU (1) | AU2003244428A1 (en) |
WO (1) | WO2003066680A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6793923B2 (en) * | 2000-11-07 | 2004-09-21 | Immunovaccine Technologies, Inc. | Vaccines with enhanced immune response and methods for their preparation |
WO2005014816A1 (en) * | 2003-08-08 | 2005-02-17 | Immunovaccine Technologies Inc. | Antigens for immunocontraception |
US9925142B2 (en) | 2005-10-07 | 2018-03-27 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment |
US10105435B2 (en) | 2011-10-06 | 2018-10-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
US10232052B2 (en) | 2007-09-27 | 2019-03-19 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
US11717563B2 (en) | 2008-06-05 | 2023-08-08 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994011019A1 (en) * | 1992-11-09 | 1994-05-26 | Zonagen, Inc. | Materials and methods for immunocontraception |
-
2003
- 2003-02-10 EP EP03737229A patent/EP1474447A2/en not_active Withdrawn
- 2003-02-10 WO PCT/CA2003/000177 patent/WO2003066680A2/en not_active Application Discontinuation
- 2003-02-10 AU AU2003244428A patent/AU2003244428A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994011019A1 (en) * | 1992-11-09 | 1994-05-26 | Zonagen, Inc. | Materials and methods for immunocontraception |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6793923B2 (en) * | 2000-11-07 | 2004-09-21 | Immunovaccine Technologies, Inc. | Vaccines with enhanced immune response and methods for their preparation |
US7824686B2 (en) | 2000-11-07 | 2010-11-02 | Immunovaccine Technologies, Inc. | Vaccines with enhanced immune response and methods for their preparation |
US8628937B2 (en) | 2000-11-07 | 2014-01-14 | Immunovaccine Technologies, Inc. | Vaccines with enhanced immune response and methods for their preparation |
US9114174B2 (en) | 2000-11-07 | 2015-08-25 | Immunovaccine Technologies Inc. | Vaccines with enhanced immune response and methods for their preparation |
US7056515B2 (en) | 2002-02-08 | 2006-06-06 | Immunovaccine Technologies Inc. | Antigens for immunocontraception |
WO2005014816A1 (en) * | 2003-08-08 | 2005-02-17 | Immunovaccine Technologies Inc. | Antigens for immunocontraception |
US9925142B2 (en) | 2005-10-07 | 2018-03-27 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment |
US10272042B2 (en) | 2005-10-07 | 2019-04-30 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment |
US10232052B2 (en) | 2007-09-27 | 2019-03-19 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
US11235069B2 (en) | 2007-09-27 | 2022-02-01 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
US11717563B2 (en) | 2008-06-05 | 2023-08-08 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
US10105435B2 (en) | 2011-10-06 | 2018-10-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
US11077184B2 (en) | 2011-10-06 | 2021-08-03 | Immunovaccine Technologies Inc. | Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response |
Also Published As
Publication number | Publication date |
---|---|
EP1474447A2 (en) | 2004-11-10 |
WO2003066680A3 (en) | 2003-11-13 |
AU2003244428A1 (en) | 2003-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WILLADSEN et al. | Comparative vaccination of cattle against Boophilus microplus with recombinant antigen Bm86 alone or in combination with recombinant Bm91 | |
TWI357906B (en) | Neutralizing epitope-based growth enhancing vaccin | |
US20080145379A1 (en) | Recombinant DNA molecules encoding aminopeptidase enzymes and their use in the preparation of vaccines against helminth infections | |
US7226996B2 (en) | Equine Fc epsilon receptor alpha protein | |
US7056515B2 (en) | Antigens for immunocontraception | |
US8030287B2 (en) | DNA vaccine against North American spring viremia of carp virus | |
WO2003066680A2 (en) | Antigens for immunocontraception | |
KR20110039517A (en) | Chloramphenicol acetyl transferase(cat)-defective somatostatin fusion protein and uses thereof | |
Tips et al. | Co-localization of locustamyotropin-and pheromone biosynthesis activating neuropeptide-like immunoreactivity in the central nervous system of five insect species | |
JP2002512253A (en) | Novel Dermatophagoides Nucleic Acid Molecules, Proteins, and Methods of Use Thereof | |
KR20100139096A (en) | Compositions, methods and kits | |
Kitchener et al. | Immunocontraception of Eastern Grey kangaroos (Macropus giganteus) with recombinant brushtail possum (Trichosurus vulpecula) ZP3 protein | |
WO1998027208A1 (en) | NOVEL FELINE Fc EPSILON RECEPTOR ALPHA CHAIN NUCLEIC ACID MOLECULES, PROTEINS AND USES THEREOF | |
US6193971B1 (en) | Dictyocaulus viviparus antigen for diagnosing lungworm infestation and for vaccination | |
US20180015155A1 (en) | Combination of protein forms for hornfly vaccination | |
US6777247B2 (en) | Nervous necrosis virus protein | |
US6455041B1 (en) | Immunogenic epitopes of the human zona pellucida protein (ZP1) | |
KR20050011909A (en) | Recombinant VP2 Protein Comprising Canine Parvovirus Neutralization Antigen Epitope And Vaccine Composition Comprising The Same | |
SURI et al. | Evaluation of recombinant protein r140, a polypeptide segment of tegumental glycoprotein Sm25, as a defined antigen vaccine against Schistosoma mansoni | |
WO1996028469A1 (en) | Hematophagous insect calreticulin nucleic acid molecules, proteins and uses thereof | |
US20240156925A1 (en) | Peptide combination, chimeric peptide, immunogenic composition, use of the peptide combination, use of the chimeric peptide, use of a composition, method for inducing an immune response and kit | |
US6764689B1 (en) | High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications | |
US7294477B2 (en) | Allergen and treatment | |
EP4310102A1 (en) | Peptide combination, chimeric peptide, immunogenic composition, use of the peptide combination, use of the chimeric peptide, use of a composition, method for inducing an immune response and kit | |
ES2441880A1 (en) | Composition containing polypeptides for the treatment of myiasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 10636620 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003737229 Country of ref document: EP Ref document number: 2003244428 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 535116 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2003737229 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003737229 Country of ref document: EP |